Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
April 22, 2022 at 06:49 am EDT
Share
Wuhan Hiteck Biological Pharma Co.,Ltd reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 608.2 million compared to CNY 517.97 million a year ago. Revenue was CNY 614.68 million compared to CNY 524.12 million a year ago. Net income was CNY 27.65 million compared to net loss of CNY 25.03 million a year ago. Basic earnings per share from continuing operations was CNY 0.26 compared to basic loss per share from continuing operations of CNY 0.24 a year ago. Diluted earnings per share from continuing operations was CNY 0.26 compared to diluted loss per share from continuing operations of CNY 0.24 a year ago.
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segmentâs businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.
WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD 